Date: 2015-05-11
Type of information: Initiation of preclinical development
phase:
Announcement:
Company: RedXPharma (UK)
Product: porcupine inhibitor
Action
mechanism: porcupine inhibitor. This small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. These are associated with tumorigenesis, metastasis, recurrence and resistance in cancer. It will have the potential to be taken orally by patients as a once daily dose.
Disease: breast cancer, head and neck cancer, pancreatic cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On May 11, 2015, Redx, the drug discovery and development company, announced that it has reached pre-clinical proof of concept stage with an advanced oncology lead which has the potential to tackle hard-to-treat cancers including pancreatic, breast and head and neck cancer. This represents the fifth program to have advanced through Redx\'s innovative development pipeline to pre-clinical proof of concept and has been achieved in just over 12 months, from a standing start. Only one other similar treatment exists, which is currently in clinical development. The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. These are associated with tumorigenesis, metastasis, recurrence and resistance in cancer. It will have the potential to be taken orally by patients as a once daily dose.
